睿知中国医院研究地图
候选清单

正在招募肺癌II/III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  2. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06417008,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Participants with newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic EGFR-sensitive mutated NSCLC (stage IIIB/IIIC/IV) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation.

    入选标准第 2 条

  3. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.

    排除标准第 6 条

    Female subjects who are pregnant, lactating, or planning to become pregnant or breastfeed during the study period or within 6 months after the last dose of the study drug.

    排除标准第 19 条

  4. ECOG performance status of 0-1.

    入选标准第 5 条

  5. At least one target lesion per the RECIST v1.1.

    入选标准第 4 条

  6. Females must not be pregnant at screening or have evidence of non-childbearing potential.

    入选标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06417008,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Males or females aged 18 - 75 years (inclusive).
  2. Participants with newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic EGFR-sensitive mutated NSCLC (stage IIIB/IIIC/IV) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation.
  3. Agree to provide fresh or archival tumor tissue.
  4. At least one target lesion per the RECIST v1.1.
  5. ECOG performance status of 0-1.
  6. Minimum life expectancy > 12 weeks.
  7. Males or Females should be using adequate contraceptive measures throughout the study.
  8. Females must not be pregnant at screening or have evidence of non-childbearing potential.
  9. Have signed Informed Consent Form.

排除标准:Exclusion Criteria:

  1. Received or are receiving the following treatments:
  2. Previous or current treatment with MET targeted therapy or EGFR targeted antibodies or antibody-drug conjugates (ADC).
  3. Traditional Chinese medicine indicated for tumors, major surgery or other local therapy within washout period to the first dose of study drug.
  4. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion.
  5. Other investigational non-anti-tumor drugs, strong CYP3A4 inhibitors, strong inducers, drugs that are sensitive substrates of BCRP or P-gp, or drugs that prolong the QT interval within the washout period.
  6. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.
  7. History of other primary malignancies.
  8. Untreated, or active central nervous system metastases.
  9. Inadequate bone marrow reserve or organ functions.
  10. Severe, uncontrolled or active cardiovascular disorders.
  11. Severe or uncontrolled systemic diseases.
  12. Severe bleeding symptoms or bleeding tendencies.
  13. Severe arteriovenous thrombosis occurred.
  14. Serious or active infection.
  15. Active infectious diseases.
  16. Interstitial lung disease (ILD).
  17. Serious neurological or mental disorders.
  18. History of hypersensitivity to any component of HS-20117 and Aumolertinib or their similar drugs.
  19. Female subjects who are pregnant, lactating, or planning to become pregnant or breastfeed during the study period or within 6 months after the last dose of the study drug.
  20. Subjects with a history of severe allergic reactions or those who have experienced severe infusion reactions
  21. Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.

引自 ClinicalTrials.gov, NCT06417008, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06417008,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06417008